Development of a novel antimicrobial strategy during pancreatoduodenectomy

Not Applicable

Recruiting

• Conditions: pancreatoduodenectomy; D016577

• Registration Number: JPRN-jRCT1040230010
• Lead Sponsor: Fujii Tsutomu

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-04-19
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

Patients are scheduled to undergo pancreaticoduodenectomy.
Patients must be at least 20 years of age at the time of enrollment.
ECOG PS status 0, 1, or 2
The patient's consent to participate in this study was obtained.

Exclusion Criteria

History of serious drug hypersensitivity or drug allergy.
Patients have obvious preoperative infection or inflammation (e.g., fever over 38.0 digree).
Patient has a serious underlying disease (cardiac, pulmonary, metabolic, renal, cirrhosis, bowel obstruction, etc.) and is considered by the surgeon to be at high risk (more than 5%) of surgery-related mortality.
Patients have dementia, psychosis, or psychiatric symptoms.
Other conditions that make them unsuitable for the study as determined by the study investigator(s).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
RMiX-PAT Treatment compliance rate

Secondary Outcome Measures

Name	Time	Method
RMiX Target coverage